Innate Pharma (IPHA) Current Assets (2017 - 2025)
Innate Pharma's (IPHA) quarterly Current Assets came in at $54.4 million in Q4 2025, down 40.66% YoY from $91.6 million in Q4 2024, and down 26.08% on a QoQ basis from $73.6 million in Q2 2025.
Innate Pharma (IPHA) Current Assets (2017 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 9 years of Current Assets data on file, last reported at $54.4 million in Q4 2025.
- Quarterly Current Assets fell 40.66% year-over-year to $54.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $54.4 million (down 40.66% YoY) and the FY2025 annual result came in at $54.4 million, down 40.66% from the prior year.
- Current Assets slipped to $54.4 million in Q4 2025, from $73.6 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $183.3 million in Q2 2022 to a low of $54.4 million in Q4 2025.
- A 5-year average of $129.7 million and a median of $149.4 million in 2021 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2021 — Current Assets plunged 99.9% — and 2022, when it gained 17.38%.
- Tracing IPHA's Current Assets over 5 years: stood at $158.2 million in 2021, then decreased by 9.8% to $142.7 million in 2022, then gained by 11.63% to $159.3 million in 2023, then slumped by 42.47% to $91.6 million in 2024, then tumbled by 40.66% to $54.4 million in 2025.
- The last three Current Assets figures came in at $54.4 million (Q4 2025), $73.6 million (Q2 2025), and $91.6 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Innate Pharma | 202.03 Mn | 202.03 Mn | - | 54.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 54.37 Mn |
| Jun 30, 2025 | 73.55 Mn |
| Dec 31, 2024 | 91.62 Mn |
| Jun 30, 2024 | 120.17 Mn |
| Dec 31, 2023 | 159.25 Mn |
| Jun 30, 2023 | 157.30 Mn |
| Dec 31, 2022 | 142.66 Mn |
| Jun 30, 2022 | 183.32 Mn |
| Dec 31, 2021 | 158.16 Mn |
| Jun 30, 2021 | 156.18 Mn |
| Dec 31, 2020 | 206.80 Mn |
| Jun 30, 2020 | 163.69 Bn |
| Dec 31, 2019 | 263.00 Mn |
| Dec 31, 2018 | 364.84 Mn |
| Dec 31, 2017 | 161.92 Mn |